New York State Common Retirement Fund raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 840,284 shares of the biopharmaceutical company’s stock after buying an additional 90,243 shares during the quarter. New York State Common Retirement Fund owned about 0.59% of Halozyme Therapeutics worth $14,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Teacher Retirement System of Texas purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $129,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $131,000. Prudential Financial Inc. grew its holdings in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $171,000. Finally, Amalgamated Bank grew its holdings in shares of Halozyme Therapeutics by 5.3% in the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 705 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on HALO. BidaskClub raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a report on Tuesday, December 12th. Barclays lowered shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and raised their target price for the company from $16.00 to $19.00 in a report on Wednesday, November 22nd. Canaccord Genuity raised their target price on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, BMO Capital Markets raised their target price on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Halozyme Therapeutics currently has a consensus rating of “Hold” and an average price target of $18.50.

Halozyme Therapeutics, Inc. (HALO) opened at $19.69 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $9.68 and a fifty-two week high of $21.10. The company has a debt-to-equity ratio of 2.01, a quick ratio of 3.37 and a current ratio of 3.46.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The firm’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.23) earnings per share. sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 0.27 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Halozyme Therapeutics, Inc. (HALO) Shares Bought by New York State Common Retirement Fund” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/halozyme-therapeutics-inc-halo-shares-bought-by-new-york-state-common-retirement-fund/1768992.html.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.